19815 Bay Branch Rd
Andalusia, Alabama 36420
(334) 222-2523
HELPLINE: 1-877-530-0002



Facebook    

 

SCAMHC is an approved Mental Health site for the National Health Service Corps Loan Repayment program.  Find out the program details and see if you qualify by visiting: http://nhsc.hrsa.gov/

SCAMHC is an Equal Opportunity Provider and Employer and maintains a Drug-Free Workplace

 

 

 

 


powered by centersite dot net
Child & Adolescent Development: Overview
Resources
Basic InformationMore InformationLatest News
Most U.S. Parents Say Vaccination Should Be Requirement for School: PollIf a Child's Schoolwork Slips, Don't Rule Out Hearing LossNurturing Childhood Boosts Odds of a Happy Adult Life: StudyKids in Poor Neighborhoods Face Higher Odds for Obesity as AdultsA Prescription for Medicating Your Child SafelyIs a Charter School the Right Choice for Your Child?Health Tip: Mental Illness Warning SignsAn Easy Recipe for Healthier Back-to-School LunchesAHA News: Understanding Connection Between Poverty, Childhood Trauma and Heart DiseaseHealth Tip: Staying Well During the School YearBackpacks Shouldn't Be a Back-to-School Burden on HealthA Kid-Friendly Emergency Room Saves LivesMany Parents Would Switch Doctors Over Vaccination Policy, Poll FindsAs School Starts, Pack That Lunch With Nutritional Goodies5 Health Tips to Promote Back-to-School SuccessPot Poisonings Among Kids, Teens Double After Medical Marijuana Law PassedFor Kids Born With HIV, Taking Needed Meds Gets Harder With Age: StudyBuilding a Better BackpackKids Getting Too Many Opioids After TonsillectomyExplaining, Easing the Horror of Mass Shootings for Your KidsFor Kids With Asthma, Allergies, New School Year Can Bring Flare-UpsAnother Video Game Risk to Watch Out ForOlder Parents May Have Better Behaved KidsAre Too Many Kids Prescribed Antihistamines?Childhood Cancer Steals Over 11 Million Years of Healthy Life: StudyFamily Home, Football Field Most Dangerous Spots for Kids' Head InjuriesMost Airplanes Not Equipped With First Aid for KidsPlastics Chemicals Meant to Replace BPA May Not Be Any Safer for KidsWhat Happens to the Children When Parents Fight?Health Tip: Giving Medicine Safely to ChildrenHow to Make Your Child's Hospital Stay Safer, Less StressfulObesity May Boost Odds for MS in KidsHealth Tip: Diarrhea in KidsOpioid Epidemic Doubled Number of U.S. Kids Sent to Foster CareSwimming Lessons a Must for EveryoneHow to Help When Your Child Weighs Too MuchHave Kids, Buy More Produce?Zika's Damage Continues in Children Infected Before BirthCDC Warns of Start to 'Season' for Mysterious Paralyzing Illness in KidsParent Who Listens Can Help Kids Thrive Despite TraumaHealth Tip: Ear Piercing For KidsReacting Against a 'Too Clean' World, Some Parents Go Too Far the Other WaySurvey Urges Grandparents to Lock Down Their Meds When Kids VisitCalifornia Took on Anti-Vaxxers, and WonHow Does Sunshine During Pregnancy Affect Learning?Surgery Helps Babies Missing a Heart Chamber Survive, But Problems LingerAbuse, Injury More Likely When Child is With Male Caregiver: StudyHow to Foster Your Child's ImaginationLow Vitamin D at Birth Linked to Kids' High Blood Pressure RiskHow Do Kids Learn To Turn Off Troublesome Tics?
Questions and AnswersVideosLinksBook Reviews
Related Topics

ADHD: Attention Deficit Hyperactivity Disorder
Childhood Mental Disorders and Illnesses
Parenting

New Drug Combats Leading Cause of Dwarfism

HealthDay News
by -- Robert Preidt
Updated: Jun 21st 2019

new article illustration

FRIDAY, June 21, 2019 (HealthDay News) -- An experimental drug increased growth rates in children with dwarfism, according to a new study.

The four-year phase 2 trial was conducted at centers in the United States, France, United Kingdom and Australia, and included 35 children, ages 5-14, with the genetic bone disorder achondroplasia, the most common type of dwarfism.

The children were divided into four groups that received daily injections of the drug vosoritide, which helps regulate bone development, in increasing amounts.

The average increase in height among the children was about 2.4 inches a year, which is close to growth rates among children of average stature, according to the study published June 18 in the New England Journal of Medicine.

On average, the children's growth rate increased by 50%, said the authors of the study, which was designed and funded by drug maker BioMarin Pharmaceutical, which also analyzed the data.

The side effects of the drug were mostly mild, according to the researchers.

Vosoritide is now being tested in a phase 3 trial in a larger group of patients ages 5-18.

Achondroplasia is caused by overactivity of a signal that stops growth, which can be compared to overwatering a plant, explained study lead author Ravi Savarirayan, a clinical geneticist at Murdoch Children's Research Institute in Melbourne, Australia.

"This drug basically kinks the hose so that the plant gets the right amount of water and can resume regular growth," Savarirayan said in an institute news release.

Achondroplasia, which affects about 1 in every 25,000 infants, is caused by a mutation in the FGFR3 gene that impairs the growth of bones in the limbs, the spine and base of the skull.

Common complications among children with achondroplasia include spinal cord compression, spinal curvature and bowed legs. About half require spinal or other surgery.

"This study is the very first report of a possible disruptive, precision therapy for children with achondroplasia, which we hope will improve their health outcomes and functioning, as well as increase their height and access to their environment," Savarirayan said.

More information

The U.S. National Library of Medicine has more on achondroplasia.